--- title: "Huatai Securities pointed out that UNITED LAB's UBT251 Phase II data is stunning, catalyzing global potential, and maintains a \"Buy\" rating" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/277136210.md" description: "Huatai Securities pointed out that UNITED LAB's UBT251 Phase II weight loss data performed excellently, demonstrating global market potential. The weight loss rate of the drug over 24 weeks is better than Eli Lilly's retatrutide, and its safety profile is good. Huatai Securities maintains a \"Buy\" rating on UNITED LAB, forecasting earnings per share of RMB 1.28, 1.19, and 1.42 for 2025 to 2027, respectively, with a target price adjusted to HKD 20.92" datetime: "2026-02-27T03:20:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277136210.md) - [en](https://longbridge.com/en/news/277136210.md) - [zh-HK](https://longbridge.com/zh-HK/news/277136210.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/277136210.md) | [English](https://longbridge.com/en/news/277136210.md) # Huatai Securities pointed out that UNITED LAB's UBT251 Phase II data is stunning, catalyzing global potential, and maintains a "Buy" rating Huatai Securities research report points out that UNITED LAB (03933.HK) announced its domestic Phase II weight loss data for UBT251 (GLP-1/GIP/GCGR), which performed impressively overall, catalyzing global potential. Its weight loss rate at a lower dose over 24 weeks outperformed Eli Lilly (LLY.US)'s retatrutide, with safety showing mostly mild to moderate (mainly gastrointestinal reactions). The firm is optimistic about the group based on the impressive Phase II data in China, as well as the recent initiation of global Phase II data with Novo Nordisk (NVO.US), which may enhance certainty, and is optimistic about the sales potential of UBT251 overseas. The firm maintains its earnings per share forecasts for the company at RMB 1.28, 1.19, and 1.42 for 2025 to 2027 respectively, and assigns a price-to-earnings ratio of 16 times for 2026, but lowers the target price from HKD 22.26 to HKD 20.92, maintaining a "Buy" rating ### 相關股票 - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Defiance Daily Target 2X Short LLY ETF (LLYZ.US)](https://longbridge.com/zh-HK/quote/LLYZ.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [VG Health (VHT.US)](https://longbridge.com/zh-HK/quote/VHT.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [UNITED LAB (03933.HK)](https://longbridge.com/zh-HK/quote/03933.HK.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md) - [Direxion Daily LLY Bull 2X Shares (ELIL.US)](https://longbridge.com/zh-HK/quote/ELIL.US.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-HK/quote/IHE.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md) - [Eli Lilly (LLY.US)](https://longbridge.com/zh-HK/quote/LLY.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-HK/quote/IXJ.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md) - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md) - [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/zh-HK/quote/520500.CN.md) - [Direxion S&P Biotech Bear 3X (LABD.US)](https://longbridge.com/zh-HK/quote/LABD.US.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md) - [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/zh-HK/quote/159570.CN.md) - [Defiance Daily Target 2X Long LLY ETF (LLYX.US)](https://longbridge.com/zh-HK/quote/LLYX.US.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Direxion Daily LLY Bear 1X Shares (ELIS.US)](https://longbridge.com/zh-HK/quote/ELIS.US.md) - [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/zh-HK/quote/562050.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) ## 相關資訊與研究 - [Eli Lilly: Foundayo will be available with prescriptions accepted immediately and shipping from April 6](https://longbridge.com/zh-HK/news/281395595.md) - [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/zh-HK/news/280952509.md) - [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/zh-HK/news/281171668.md) - [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/zh-HK/news/280951810.md) - [Options Traders Pick Up Pharma Stock After Eli Lilly Buyout](https://longbridge.com/zh-HK/news/281233839.md)